Northwest Biotherapeutics (NWBO) Total Current Liabilities (2010 - 2026)

Northwest Biotherapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $83.0 million for Q1 2026.

• In Q1 2026, Total Current Liabilities changed 0.1% year-over-year to $83.0 million; the TTM figure through Mar 2026 stood at $83.0 million (changed 0.1% YoY), while the FY2025 annual figure was $91.7 million, up 34.31% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $83.0 million, down from $91.7 million in the prior quarter.
• The five-year high for Total Current Liabilities was $130.0 million in Q1 2022, with the low at $39.9 million in Q2 2023.
• The 5-year median for Total Current Liabilities is $83.0 million (2026), against an average of $78.3 million.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities tumbled 72.79% in 2022, then jumped 51.04% in 2024.
• Northwest Biotherapeutics' Total Current Liabilities stood at $126.0 million in 2022, then slumped by 64.13% to $45.2 million in 2023, then soared by 51.04% to $68.3 million in 2024, then soared by 34.31% to $91.7 million in 2025, then fell by 9.52% to $83.0 million in 2026.
• Business Quant data shows NWBO's Total Current Liabilities at $83.0 million in Q1 2026, $91.7 million in Q4 2025, and $87.9 million in Q3 2025.